Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of the SABR-COMET Randomized Trial

Qu, XM; Chen, YJ; Zaric, GS; Senan, S; Olson, RA; Harrow, S; John-Baptiste, A; Gaede, S; Mulroy, LA; Schellenberg, D; Senthi, S; Swaminath, A; Kopek, N; Liu, M; Warner, A; Rodrigues, GB; Palma, DA; Louie, AV

Qu, XM; Louie, AV (corresponding author), Western Univ, London Hlth Sci Ctr, London, ON, Canada.; Qu, XM; Louie, AV (corresponding author), Western Univ, Schulich Sch Med & Dent, London, ON, Canada.; Louie, AV (corresponding author), Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON, Canada.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021; 109 (5): 1176

Abstract

Purpose: The phase 2 randomized study SABR-COMET demonstrated that in patients with controlled primary tumors and 1 to 5 oligometastatic lesions, SABR......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索